SIRT With Tremelimumab and Durvalumab for Resectable HCC

This study is testing whether combining a targeted radiation therapy directly to liver tumors (called SIRT, which uses tiny radioactive beads), along with two immunotherapy drugs (tremelimumab and durvalumab), can shrink liver cancer enough to allow surgery in people who haven't been treated before. **You may be eligible if...** - You are 18 or older and weigh more than 30 kg - You have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC) - Your cancer has not been treated before - Your tumor can potentially be removed with surgery - Your liver is functioning well - Your blood counts, liver, and kidney tests are within acceptable ranges - You are able to use contraception if you can become pregnant **You may NOT be eligible if...** - You have already received any treatment for liver cancer - You have had a major surgery or serious injury in the past 6 weeks - You have had an organ transplant - You have an active autoimmune condition (like lupus, Crohn's, or rheumatoid arthritis) - You have HIV/AIDS, active hepatitis B, or active hepatitis C - You are currently taking immune-suppressing medications - You have brain tumors or brain metastases - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.